• LAST PRICE
    2.5900
  • TODAY'S CHANGE (%)
    Trending Down-0.0500 (-1.8939%)
  • Bid / Lots
    2.5900/ 2
  • Ask / Lots
    2.6300/ 5
  • Open / Previous Close
    2.6400 / 2.6400
  • Day Range
    Low 2.5800
    High 2.6700
  • 52 Week Range
    Low 1.3500
    High 4.3999
  • Volume
    4,705
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 2.64
TimeVolumeAXLA
09:32 ET23712.58
09:52 ET1002.6
10:01 ET1002.61
10:14 ET1002.61
10:26 ET2002.645
10:28 ET9492.61
10:30 ET1092.59
10:39 ET1002.59
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesAXLA
Axcella Health Inc
123.6M
-1.5x
---
United StatesGNTA
Genenta Science SPA
117.2M
-20.2x
---
United StatesCKPT
Checkpoint Therapeutics Inc
120.4M
-1.6x
---
United StatesACHL
Achilles Therapeutics PLC
125.1M
-1.9x
---
United StatesVNRX
VolitionRX Ltd
115.6M
-3.3x
---
United StatesIOBT
IO Biotech Inc
109.5M
0.0x
---
As of 2022-08-18

Company Information

Axcella Health Inc. is a clinical-stage biotechnology company focused on a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs). The Company’s product candidates are comprised of multiple EMMs that are engineered in distinct combinations and ratios with the goal of simultaneously impacting multiple biological pathways. AXA1665 is being developed as a product candidate for the reduction in risk of overt hepatic encephalopathy (OHE) recurrence in adult patients with liver cirrhosis. Its AXA1125 AXA1125 is being developed as an oral product candidate for the treatment of non-alcoholic steatohepatitis (NASH). The Company’s pipeline includes lead therapeutic candidates for the treatment of NASH, for the treatment of long COVID (also known as Post COVID-19 Condition and Post-Acute Sequelae of COVID-19, or PASC) associated fatigue, and for the reduction in risk of recurrent OHE.

Contact Information

Headquarters
840 Memorial DrCAMBRIDGE, MA, United States 02139-3789
Phone
617-868-0949
Fax
617-441-6243

Executives

Chairman of the Board
David Epstein
President, Chief Executive Officer, Director
William Hinshaw
Chief Financial Officer
Robert Crane
Chief Human Resource Officer, Senior Vice President
Virginia Dean
Executive Vice President, Chief Medical Officer
Shreeram Aradhye

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$123.6M
Revenue (TTM)
$0.00
Shares Outstanding
52.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.75
Book Value
$0.56
P/E Ratio
-1.5x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.